BCR-ABL1T315I arises in the ABL kinase domain interfering with binding to TKIs like imatinib and others [8, 9] accounting for 15–20% of mutations found in CML patients [10, 11]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.